SCHEMBL10074129

SCHEMBL10074129

CC(C)NC(CC(=O)NCC(C)(C)CNC(=O)[C@@H](O)[C@H](N)COCc1ccccc1)Cc1cc(F)ccc1F

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
REN P00797 5/20 0.37
LAP3 P28838 2/20 0.35
ANPEP P15144 1/20 0.35
RNPEP Q9H4A4 1/20 0.35
DNPEP Q9ULA0 1/20 0.35
CTSS P25774 1/20 0.35
DPP4 P27487 6/20 0.34
DPP7 Q9UHL4 2/20 0.34
DPP9 Q86TI2 2/20 0.34
KCNH2 Q12809 3/20 0.33
FAP Q12884 3/20 0.33
ADRB2 P07550 2/20 0.33
ADRB1 P08588 2/20 0.33
ADRB3 P13945 2/20 0.33
PREP P48147 1/20 0.33
CTSB P07858 1/20 0.33
PSMB11 A5LHX3 1/20 0.33
PSMD11 O00231 1/20 0.33
PSMD12 O00232 1/20 0.33
PSMD14 O00487 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10078267 1.00 REN (0.37) RENLAP3ANPEPRNPEPDNPEP
SCHEMBL10074716 1.00 REN (0.37) RENLAP3ANPEPRNPEPDNPEP
SCHEMBL10074326 0.90 DPP4 (0.41) RENDPP4DPP7DPP9KCNH2
SCHEMBL10074457 0.90 DPP4 (0.41) RENDPP4DPP7DPP9KCNH2
SCHEMBL10074711 0.90 REN (0.39) RENLAP3ANPEPRNPEPDNPEP
SCHEMBL10074471 0.89 SYK (0.37) RENCTSSADRB2ADRB1ADRB3
SCHEMBL10074722 0.89 SYK (0.37) RENCTSSADRB2ADRB1ADRB3
SCHEMBL10078259 0.89 SYK (0.37) RENCTSSADRB2ADRB1ADRB3
SCHEMBL10077384 0.89 REN (0.34) RENLAP3ANPEPRNPEPDNPEP
SCHEMBL10074717 0.87 REN (0.35) RENLAP3ANPEPRNPEPDNPEP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2418196-A1 Dual alanyl-aminopeptidase and dipeptidyl-peptidase IV inhibitors IMTM GmbH (DE) 2012-02-15 EP disclosed
US-20120028995-A1 NOVEL COMPOUNDS FOR MEDICAL USE AS PEPTIDASE EFFECTORS IMTM GMBH (DE) 2012-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120028995-A1 NOVEL COMPOUNDS FOR MEDICAL USE AS PEPTIDASE EFFECTORS SERPINB1, CMA1, CPA3 REN 449/4885LAP3 186/4885ANPEP 36/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.